AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. Roche, a familiar sight at the top of PatientView’s cancer rankings, claimed first place ahead of AstraZeneca and Novartis.
Source: FiercePharma
